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Objective: We sought to compare the long-term clinical outcomes of patients who
underwent isolated aortic valve replacement with single-disc and bileaflet mechan-
ical heart valves.
Methods: From May 1975 through October 2001, 590 single-disc valves (7 models)
were used for isolated valve replacement, and from November 1980 through July
2002, 1283 bileaflet valves (10 models) were used for isolated valve replacement.
Detailed follow-up was performed to a maximum of 27.4 and 21.9 years with a total
of 6872 and 5811 patient-years for single-disc valves and bileaflet valves, respec-
tively. Survival and valve-related events were analyzed.
Results: Single-disc valves were mainly implanted from 1975 through 1995,
whereas bileaflet valves were mainly implanted from 1987 through 2002; thus the
years of concurrent use were 1987 through 1995. The bileaflet valve had a signif-
icantly lower explantation rate, whereas the single-disc valve had a significantly
lower thromboembolism rate. No significant differences were detected in early
mortality, long-term survival, and other valve-related complications. When limiting
the comparison to the concurrent period of 1987 through 1995, no significant
difference was detected in survival or in any valve-related complication.
Conclusion: Single-disc and bileaflet valves provide similar clinical performance.
The predominant use of bileaflet valves is not based on clinical outcomes.
The first successful mechanical heart valves, beginning in the early1960s, were of the caged-ball design.1 Then came the low-profilesingle-leaflet disc (L1) valves during the 1970s,2 followed by bileaf-let (L2) valves since the early 1980s.3 L1 valves have a housing witha single free-floating circular disc. L2 valves have 2 semicircularleaflets that are mounted on hinges within a housing that open and
close simultaneously. Nowadays, most mechanical valves being implanted are L2
valves. It is generally perceived that, being more “modern,” L2 valves must be more
advanced. However, the question of which one has better long-term performance
remains unanswered.
Materials and Methods
Patients
From May 1975 through October 2001, 590 L1 valves and 1283 L2 valves were implanted
in 1873 consecutive patients undergoing isolated aortic valve replacement at the Department
of Cardiothoracic and Respiratory Sciences, Second University of Naples, V Monaldi
Hospital. There were 7 models of L1 valves and 10 models of L2 valves. These 17 models
were divided into 10 subgroups on the basis of similarity of design and manufacturer (Table
1). The choice of prosthesis was according to surgeon preference, and no overt selection
criteria were used. The use of valve types over time is shown in Figure 1. L1 valves were
From Medical Data Research,a Providence
Health System, Portland, Ore; the Depart-
ment of Cardiothoracic and Respiratory
Sciences,b Second University of Naples,
Naples, Italy; and the Cardiac Surgery
Unit,c University Magna Graecia, Catan-
zaro, Italy.
Received for publication May 8, 2003; re-
visions requested June 16, 2003; accepted
for publication Aug 18, 2003.
Address for reprints: YingXing Wu, MD,
Medical Data Research, Providence Health
System, 9205 SW Barnes Rd #33LL, Port-
land, OR 97225 (E-mail: yingxing.wu@
providence.org).
J Thorac Cardiovasc Surg 2004;127:1171-9
0022-5223/$30.00
Copyright © 2004 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2003.08.030
Wu et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 4 1171
A
CD
mainly used from 1975 through 1995, and L2 valves were mainly
used from 1987 through 2002, with concurrent use of both types
from 1987 through 1995 (Figure 1, shaded area). The percentage
use ratio of L1:L2 valves was 97%:3% from 1975 through 1986
and 2%:98% from 1996 through 2002. From 1987 through 1995,
the use ratio was 49%:51%. Because the 2 types of valves were
implanted in different eras, many improvements over time could
make the results favor the recent valve type. Thus the analyses of
the patients operated on from 1987 through 1995, when the 2 types
of valve were used concurrently, are considered as the primary
analyses, although results are also given for the entire series of
valves.
Surgical Technique
Valve replacement was performed by the same group of surgeons,
and the surgical technique remained substantially the same over
the years. Standard cardiopulmonary bypass was performed in all
cases. Bubble oxygenators were used until January 1990, and since
then, hollow-fiber membrane oxygenators were used routinely.
Myocardial protection was achieved with mild systemic hypother-
mia (26°C), antegrade crystalloid cardioplegia, and topical cooling
with the Shumway technique. Kirsh cardioplegia was used until
March 1981, and since then, St Thomas 1 solution has been used
in all cases. Cardioplegia has been infused through the aortic root
in patients with predominant aortic stenosis; in patients with valve
regurgitation, cardioplegia was delivered through direct cannula-
tion of the coronary ostia.
All prostheses were inserted in the intra-annular position by
using unpledgeted, interrupted, simple Tevdek 2-0 stitches. Single-
disc valves were oriented with the main orifice toward the non-
coronary sinus and bileaflet valves with their axis perpendicular to
the septum. Leaflet mobility was always evaluated at the end of the
procedure.
Anticoagulation Methods
Anticoagulation with warfarin was begun on the second postoper-
ative day for all patients. The criterion for an adequate anticoag-
ulation state was a prothrombin activity of 28%  8%, which in
our laboratory equals an international normalized ratio of 2.8 
0.8. International normalized ratio assay was performed at least
once a month. Data concerning anticoagulation status for each
patient were recorded. New hospital admissions either for cardiac
or noncardiac causes were recorded as well.
Follow-up
Our follow-up methodology was about 60% prospective and 40%
retrospective.
Our collection of follow-up data has high accuracy because our
referrals are very restricted, and only a small percentage of patients
come to us from other centers. Almost all patients visit our
outpatient clinic almost yearly. Nearly 70% of our population is
followed in our anticoagulation clinic by one of us every day.
About 20% of patients are managed in 2 other satellite anticoag-
ulation clinics and followed up by their own physicians, who are
well informed and aware of our anticoagulation policy recommen-
dations. Patients who are not followed up at our clinic or by their
general practitioner are contacted by telephone or by mail to assess
their healthy status. Such work is periodically done by our students
doing medical theses. We record any event that occurred since the
operation into a dedicated follow-up database. When we decided to
begin this project, we initially checked our database, collecting the
most recent follow-up data for 56% of the patients. For patients
lost at our follow-up clinic or with their most recent examination
more than 6 months old, we checked their status by telephone calls
to the patient or his or physician. For patients who did not reply to
our telephone call or letter, an official letter was sent to the Polls
Department of City Office to assess whether the patient was dead
or alive or had moved to another city, and in such cases recontact
was made by means of telephone or mail to the latest address. For
patients who died during the follow-up period, we interviewed the
closest relative.
Statistics
Data are presented in accordance with the Guidelines for Report-
ing Morbidity and Mortality After Cardiac Valvular Operations.4
Early events, including death, are defined as occurring before
hospital discharge or within 30 days after the operation, whichever
is longer. Late events were all other events. Comparison between
the preoperative characteristics of the 2 valve groups was made by
using the 2 test for discrete variables and the Student t test for
continuous variables. Univariate comparison of operative mortality
was also made by using the 2 test. Actuarial survival curves and
event-free curves were produced by using the Kaplan-Meier
method, with the log-rank test for comparison. Cox regression was
used to estimate the effect of risk factors on survival and explan-
tation. Linearized rates, calculated as the number of late events
divided by total late follow-up years and then multiplied by 100 to
TABLE 1. Valve groups with 2-letter abbreviations (in pa-
rentheses) used to label Figures 4 to 7
Valve model (abbreviations)
No. of
valves
Mean follow-up
(y)
Single disc (L1)
Bjork Shiley (BS) 80 12
Medtronic Hall (MH) 36 8
Medical CV (MC)
Lillehei-Kaster 6 8
Omnicarbon 8 6
Sorin Monodisc (SM)
Sorin (standard model) 290 13
Sorin Allcarbon 59 9
Sorin Carbocast 111 12
Bileaflet (L2)
ATS-Medical (AM) 51 4
Edwards MIRA (EM) 266 3
Sorin Bicarbon (SB) 253 4
Carbomedics (CM)
Carbomedics (standard model) 90 8
Carbomedics HP 202 8
Edwards Lifescience (EL)
Duromedics 17 12
TEKNA 13 4
St. Jude Medical (SJ)
St. Jude (standard model) 335 4
St. Jude HP 52 4
St. Jude Regent 4 1
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convert to the percentage per patient-year, were used to describe
late valve-related complications. The 95% confidence intervals
(CIs) for individual linearized rates were calculated with a method
suggested by Cox.5 The Cochran test6 was used to test the heter-
ogeneity of the linearized rates within each group. Because no
significant heterogeneity was found among valves of the same
type, likelihood ratio tests were used to compare the weighted
mean linearized rates between the 2 valve groups. Statistical anal-
ysis was done with SPSS10 (SPSS Inc, Chicago, Ill) and S-PLUS
2000 (Insightful Corp, Seattle, Wash) software.
Results
The patients receiving L1 and L2 implants during the con-
current era had similar clinical profiles (Table 2). Because
there were very few cases of L2 valves from 1975 through
TABLE 2. Clinical material for patients undergoing aortic valve replacement by 3 time frames
1975-1986 1987-1995 (Concurrent) 1996-2002
Single disc
(L1)
Single disc
(L1)
Bileaflet
(L2) P value
Bileaflet
(L2)
No. of patients 249 326 337 938
Age, y 44 13 53 14 54 14 .9 60 14
Female sex 54 (22) 71 (22) 129 (38) .001 393 (42)
Valve pathology .01
Stenosis 55 (22) 93 (29) 126 (37) 482 (51)
Regurgitation 113 (45) 121 (37) 99 (29) 257 (27)
Combined 74 (30) 102 (31) 92 (27) 181 (19)
Prosthetic dysfunction 7 (3) 10 (3) 20 (6) 18 (2)
Valve size (mm) 23 2 23 2 22 2 .001 22 2
Previous AVR 7 (3) 10 (3) 20 (6) .08 18 (2)
Follow-up, y
Mean 15.2 7.4 9.4 4.5 8.6 3.7 .02 3.0 2.0
Maximum 27.4 15.6 15.5 6.8
Total 3777 3062 2910 2768
Postoperative NYHA class .6
I 126 (75) 200 (81) 217 (83) 742 (88)
II 34 (20) 40 (16) 42 (16) 92 (11)
III 5 (3) 5 (2) 3 (1) 5 (1)
IV 3 (2) 1 (0) 0 (0) 4 (1)
AVR, Aortic valve replacement; NYHA, New York Heart Association.
Figure 1. The use of L1 and L2 valves over time. The shaded area indicates the time period when the use of the
2 valve types overlapped.
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1986 and very few cases of L1 valves from 1996 through
2002, these were omitted from Table 2.
Follow-up
The closing date of this study was October 2002. For the L1
valve group, there were 6872 cumulative patient-years of
follow-up, with a mean of 11.6 years and a maximum of
27.4 years. For the L2 valve group, there were 5810 cumu-
lative patient-years of follow-up, with a mean of 4.5 years
and a maximum of 21.9 years. The follow-up was 100%
complete for both groups. For the concurrent subset of
patients from 1987 through 1995, the total follow-up was
3062 patient-years (mean, 9.4; maximum, 15.6) for L1
valves and 2910 patient-years (mean, 8.6; maximum, 15.5)
for L2 valves.
Patient Survival
Early mortality was 7.3% (43/590) for L1 recipients versus
5.5% (71/1283) for L2 recipients (P  .140). For the
concurrent subset, early mortality was 7.4% (24/326) for L1
recipients versus 6.5% (22/337) for L2 recipients (P 
.673). For the entire series, overall survival was 79% (95%
CI, 76%-82%) versus 79% (95% CI, 75%-83%) at 10 years
and 68% (95% CI, 63%-72%) versus 75% (95% CI, 70%-
80%) at 20 years (P  .359) for L1 and L2 valves, respec-
tively. For the concurrent subset, the overall survival was
similar between patients receiving L1 and L2 valves: 70%
Figure 2. Actuarial overall survival after valve replacement for patients operated on from 1987 through 1995
(shaded area in Figure 1). Numbers above the horizontal axis indicate the number of patients at risk.
TABLE 3. Cause of death: All time frames
Cause of death
Single disc
(L1)
Bileaflet
(L2)
Early Late Early Late
Cardiac death
Valve related
Stroke — — — 3
Hemorrhage — 1 — 1
Endocarditis — 1 — 2
Leak — 6 — —
Fibrous tissue overgrowth — 1 — 1
Sudden death — 20 — 13
Nonvalve related
Acute myocardial infarction 3 11 10 7
Rupture of aorta, dissection 2 3 1 1
Arrhythmia 5 — 6 —
Congestive heart failure — 9 1 9
Low output syndrome 15 — 14 —
Mitral valve disease — 1 — —
Multiple organ failure 6 2 9 1
Noncardiac death 12 64 30 56
Total 43 119 71 94
TABLE 4. Cause of explantation: All time frames
Single disc (L1) Bileaflet (L2)
Endocarditis 7 (1) 6 (2)
Thrombosis 2
Perivalvular leak 21 (5) 4
Fibrous tissue overgrowth 1 (1) 1 (1)
Aortic dissection 1
Ascending aorta aneurysm 1 (1)
Total 32 (8) 12 (3)
Numbers in parentheses indicate fatal explantation.
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(95% CI, 63%-77%) versus 73% (95% CI, 68%-79%) at 15
years (P  .758, Figure 2). In the Cox regression for this
subset, age and previous aortic valve replacement were
found to be significant risk factors, but valve type was not
(P .718). Causes of death for the entire series are given in
Table 3.
Reoperation
In the entire series 44 L1 recipients required reoperation: 32
resulted in valve explantation, and 8 were fatal (Table 4).
Two thirds of explantations were caused by perivalvular
leak. One explantation in this group happened within the
30-day postoperative period. Twenty-one L2 recipients re-
quired reoperation: 12 resulted in valve explantation, and 3
were fatal. In the entire series the L2 group had a higher
freedom from explantation than the L1 group, with 98%
(95% CI, 96%-99%) versus 95% (95% CI, 92%-96%) at 10
years and 93% (95% CI, 84%-97%) versus 91% (95% CI,
86%-94%) at 20 years (P .012). For the concurrent subset
of patients, the L2 valve group had a higher, although not
significant, result: 95% (95% CI, 89%-98%) versus 95%
(95% CI, 91%-97%; P  .146) at 15 years (Figure 3). Cox
regression with the concurrent subset found previous aortic
valve replacement (P  .001) to be a significant risk factor,
but valve type was not (P  .101).
Valve-related Complications
Death and the valve-related complications of explantation,
thromboembolism, hemorrhage, perivalvular leak, endocar-
ditis, and prosthesis valve thrombosis were summarized as
linearized rates for the entire series of 4 L1 subgroups and
6 L2 subgroups (Table 5). The complication rates varied
Figure 3. Freedom from explantation after valve replacement for patients operated on from 1987 through 1995
(shaded area in Figure 1). Numbers above the horizontal axis indicate the number of patients at risk.
TABLE 5. Comparisons of linearized event rates within and between valve groups: All time frames
Events
Single disc (L1) Bileaflet (L2) Likelihood
ratio
P value†
Linearized rate
(95% CI)
Cochran
P value*
Linearized rate
(95% CI)
Cochran
P value*
Thromboembolism 0.059 (0.020-0.14) .9 0.26 (0.15-0.42) .7 .003
Hemorrhage 0.073 (0.028-0.16) .3 0.070 (0.024-0.17) .2 .9
Leak 0.38 (0.25-0.55) .7 0.28 (0.17-0.44) .2 .3
Endocarditis 0.16 (0.086-0.28) .2 0.16 (0.078-0.29) .8 1
Thrombosis 0.029 (0.0061-0.094) .9 0.018 (0.0019-0.082) .9 .7
Explantation 0.45 (0.31-0.64) .6 0.21 (0.11-0.36) .8 .02
Death 1.7 (1.5-2.1) .4 1.7 (1.3-2.0) .1 .7
CI, Confidence interval.
*Cochran tests of differences within valve models in each group.
†Likelihood ratio tests of differences between valve group.
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between and within the L1 and L2 subgroups (Figures 4-7).
To properly compare the pooled complication rates be-
tween L1 and L2 valves, we needed to test the assumption
that the complication rates of all the subgroups within the
same group were homogeneous.7 For death and all valve-
related complications, the Cochran test did not show signif-
icant heterogeneity within either valve group. Therefore
weighted mean linearized rates were compared between the
L1 and L2 groups (Table 5). The L2 group had a lower
explantation rate, whereas the L1 group had a lower throm-
boembolism rate. The 2 groups had very similar linearized
rates for hemorrhage, endocarditis, leak, thrombosis, and
Figure 4. Thromboembolism rates for L1 and L2 valves (all time frames). Circles indicate L1 valves, and paired
semicircles indicate L2 valves. Dashed horizontal lines indicate weighted mean rates for each valve group.
Two-letter valve-model abbreviations are specified in Table 1. Numbers at the bottom of the graph show the
number of events (Events) and total late follow-up years (Pt-yrs) for each valve model. For statistical comparisons
between L1 and L2 valves during the concurrent era only, see Table 6. For model abbreviations, see Table 1.
Figure 5. Hemorrhage rates for L1 and L2 valves. See legend to Figure 4.
Surgery for Acquired Cardiovascular Disease Wu et al
1176 The Journal of Thoracic and Cardiovascular Surgery ● April 2004
A
CD
late mortality. Very few valve thromboses were observed in
either group.
Separating all the valves by the 3 time periods created 4
well-balanced groups (Table 6). L1 and L2 valves showed
consistent complication rates over the different time peri-
ods. When the comparison between L1 and L2 is limited to
1987 through 1995, the period of concurrent use, no signif-
icant difference was detected for any complications.
Discussion
There is a common perception that L2 valves, being a later
generation of mechanical valves, must be superior to L1
valves with regard to both hemodynamic performance and
clinical outcomes. However, some in vitro and in vivo
studies have demonstrated that an L1 valve can offer better
hemodynamic performance than an L2 valve with both
valves implanted in their optimum orientation in the aortic
Figure 6. Leak rates for L1 and L2 valves. See legend to Figure 4.
Figure 7. Endocarditis rates for L1 and L2 valves. See legend to Figure 4.
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position.8-10 This is because the L1 valve’s asymmetric
design matches the natural eccentric flow profile of the
aortic root. However, whether the specific hemodynamic
advantages can be translated into better clinical outcome is
not clear. The preference for the L2 valves could also be due
to less noise or a perception of more safety as a result of the
redundancy of the 2-leaflet design.
Several studies have compared the clinical outcomes of
these 2 types of valves on the basis of their experience on 2
or 3 specific valve models.11-14 A comparison of many
published reports found similar event rates between L1 and
L2 valves.15 In fact, even the earliest caged-ball Starr-
Edwards valve, for which the design has not been changed
since 1966, offers very good performance.16 Therefore we
summarized our experience of the performance of 590 L1
valves and 1283 L2 valves. We hoped this study could
provide some information about the long-term performance
of these 2 main types of mechanical valves or, if not, to at
least open to question the issue of bileaflet valve superiority.
Even though we gradually switched from L1 to L2 valves
from 1987 through 1995 (Figure 1), looking back now at our
28 years of experience, it seems that this switchover was not
evidence based.
There was no significant difference in overall long-term
survival for L1 and L2 valves (Figure 3). When the entire
series was used, L1 valves had a lower thromboembolism
rate but a higher explantation rate, which was primarily
because of perivalvular leak. The diagnosis of perivalvular
leak was always based on echocardiography. For perival-
vular leak, surgeons were more likely to replace the old L1
valve with the newer L2 device but to repair a sterile,
leaking L2 valve. When limiting the comparison to the
concurrent patients operated on from 1987 through 1995,
however, no significant difference was detected in any
valve-related complications. The complication rates were
low in our study, which could be due to our relatively young
patient age; many complications, such as death and throm-
boembolism, are related to patient age.
The study was a mixture of prospective and retrospective
follow-up, and only a limited number of patient character-
istics were available for risk adjustment. There are large
numbers of valves of both types and long-term follow-up
but a small number of valves for some valve models.
Moreover, there are few events that could affect the detec-
tion of heterogeneity. It is a statistical challenge to compare
2 nonrandomized clinical series. If they are concurrent,
there are unknown patient selection factors. If they are
consecutive, there are changes over time, which can im-
prove the more recent results. This study included 3 eras: an
early one in which L1 valves were used almost exclusively,
a recent one in which L2 valves were used almost exclusively,
and a middle one in which both were used concurrently and in
almost equal numbers. We were thus able to compare the
overall results, which included periods of unselected (almost
consecutive) use, and the concurrent results, which matched
for time frame of surgical intervention.
The results of the present study show that L1 and L2
valves offer similar good clinical performance. The pre-
dominant use of L2 valves has not been scientifically jus-
tified on the basis of clinical outcomes.
Three reviewers for the Journal provided thoughtful comments
and suggestions and were responsible for several improvements.
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